↓ Skip to main content

Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199

Overview of attention for article published in Molecular Cancer Therapeutics, December 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
1 news outlet
twitter
1 tweeter

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
Published in
Molecular Cancer Therapeutics, December 2021
DOI 10.1158/1535-7163.mct-20-1132
Pubmed ID
Authors

Beatrice T. Wang, Tasnim Kothambawala, Ling Wang, Thomas J. Matthew, Susan E. Calhoun, Avneesh K. Saini, Maya F. Kotturi, Genevive Hernandez, Eric W. Humke, Marvin S. Peterson, Angus M. Sinclair, Bruce A. Keyt

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Lecturer 3 27%
Student > Master 1 9%
Unknown 7 64%
Readers by discipline Count As %
Medicine and Dentistry 3 27%
Immunology and Microbiology 1 9%
Unknown 7 64%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2022.
All research outputs
#4,173,253
of 21,407,661 outputs
Outputs from Molecular Cancer Therapeutics
#761
of 3,701 outputs
Outputs of similar age
#117,522
of 468,242 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#16
of 81 outputs
Altmetric has tracked 21,407,661 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,701 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 468,242 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 81 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.